Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amedeo Mugellini & Valentina Nieswandt. (2012) Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. Expert Opinion on Pharmacotherapy 13:18, pages 2699-2709.
Read now
Read now
Csaba Farsang. (2011) Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vascular Health and Risk Management 7, pages 605-622.
Read now
Read now
Peter Baumgart, Ingomar Naudts & Gerhard Kiel. (2011) Introducing candesartan 32 mg plus hydrochlorothiazide 25 mg in previously untreated patients with severe essential hypertension. Pragmatic and Observational Research 2, pages 5-12.
Read now
Read now
E Van der Merwe & A Carboni. (2011) Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients. South African Family Practice 53:6, pages 525-532.
Read now
Read now
Alexander Joost, Heribert Schunkert & Peter Walter Radke. (2011) Candesartan cilexetil: an update. Expert Opinion on Pharmacotherapy 12:11, pages 1769-1780.
Read now
Read now
Articles from other publishers (2)
Peter Bramlage, Hartmut Buhck & Claudia Zemmrich. (2014) Candesartan Cilexetil 32 mg/Hydrochlorothiazide 25 mg in Unselected Patients with High or Very High Cardiovascular Risk: Efficacy, Safety, and Metabolic Impact. Clinical Drug Investigation 34:4, pages 241-249.
Crossref
Crossref
Hiromichi Suzuki, Yukio Shimada & Kenji Fujiwara. (2012) Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan. Therapeutic Advances in Cardiovascular Disease 6:6, pages 237-244.
Crossref
Crossref